UT Southwestern-founded Taysha Gene Therapies surpassed its goal after underwriters bought additional shares.
Taysha Gene Therapies, a US-based central nervous system drug developer spun out of University of Texas Southwestern (UT Southwestern) Medical Center, has raised $181m in an upsized initial public offering on the Nasdaq Global Select Market.
Taysha began trading on September 24 and closed the offering yesterday after issuing 7.8 million shares priced at $20.
Goldman Sachs, Morgan Stanley, Jefferies acted as joint book-running for the offering, while Chardan Capital Markets was appointed lead manager. They exercised their 30-day option to purchase up to an additional 1.2 million shares.
Taysha originally filed for the listing in September 2020.
Founded in 2019, Taysha Gene Therapies targets monogenic central nervous system (CNS) diseases in which the body is unable to express a specific protein because of a lone faulty gene or gene pair.
The spinout has a portfolio of 17 gene therapies as well as four…
